Form 4: KKR Sells 6 Million Shares of BridgeBio Pharma (BBIO) in Block Trade

KKR Genetic Disorder L.P. sold 6 million shares of BridgeBio Pharma at $34.20 per share.

Summary

• KKR Genetic Disorder L.P. sold 6,000,000 shares of BridgeBio Pharma, Inc. (BBIO) common stock on May 12, 2025.
• The sale was executed as a block trade at a price of $34.20 per share.
• Following the transaction, KKR Genetic Disorder L.P. indirectly holds 13,260,971 shares.
• The shares are indirectly held through a chain of entities including KKR Genetic Disorder GP LLC, KKR Group Partnership L.P., KKR Group Holdings Corp., KKR Group Co. Inc., KKR & Co. Inc., and KKR Management LLP.
• Henry R. Kravis and George R. Roberts, founding partners of KKR Management LLP, disclaim beneficial ownership of the reported securities.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to a stock sale. It doesn't inherently convey positive or negative sentiment, but the market's reaction to the sale could influence sentiment.

Industry Context

Block trades by major shareholders are common and can influence short-term stock price movements. The market will likely analyze the reasons behind KKR's sale and its potential impact on BridgeBio Pharma's future prospects.

Comparison to Industry Standards

• It's difficult to compare this specific transaction to industry standards without knowing the specific reasons behind KKR's sale.
• However, large institutional investors like KKR often rebalance their portfolios, and such sales are not necessarily indicative of negative sentiment towards the company.
• Comparable transactions would involve other major shareholders in the biotech industry selling significant blocks of shares.

Stakeholder Impact

• Shareholders may react to the news of KKR's sale, potentially impacting the stock price.
• The sale could influence market perception of BridgeBio Pharma's prospects.

Key Dates

Keywords

BridgeBio Pharma, BBIO, KKR, stock sale, block trade, Form 4, beneficial ownership, securities